Biotech CEOs credit JOBS Act for IPO wave

There's been a lot written recently about the sudden biotech IPO craze that has run amuck in recent months. The Scientist went out and asked several CEOs about the major reasons behind the sudden burst of offerings, and found a lot of support for the federal Jumpstart Our Business Startups (JOBS) Act. "The JOBS Act provided a safe harbor under which companies could talk to investors, educate them, and get feedback about whether the company was attractive to those investors," said Chimerix ($CMRX) CEO Kenneth Moch, who had a breakout IPO earlier in the year. So far, 30 biotechs have gone public in 2013 as the industry sees the biggest wave form since 2000. And now the evidence of investor support is plain to everyone. Story

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.